Analytical Data
-
基因名
AGE
- Application
-
别名
AGE；N-acylglucosamine 2-epimerase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P51606
-
表达区间
1-427aa
-
氨基酸序列
MSKGLPARQDMEKERETLQAWKERVGQELDRVVAFWMEHSHDQEHGGFFTCLGREGRVYDDLKYVWLQGRQVWMYCRLYRTFERFRHAQLLDAAKAGGEFLLRYARVAPPGKKCAFVLTRDGRPVKVQRTIFSECFYTMAMNELWRATGEVRYQTEAVEMMDQIVHWVQEDASGLGRPQLQGAPAAEPMAVPMMLLNLVEQLGEADEELAGKYAELGDWCARRILQHVQRDGQAVLENVSEGGKELPGCLGRQQNPGHTLEAGWFLLRHCIRKGDPELRAHVIDKFLLLPFHSGWDPDHGGLFYFQDADNFCPTQLEWAMKLWWPHSEAMIAFLMGYSDSGDPVLLRLFYQVAEYTFRQFRDPEYGEWFGYLSREGKVALSIKGGPFKGCFHVPRCLAMCEEMLGALLSRPAPAPSPAPTPACRGAE
-
分子量
48.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AGE (Advanced Glycation End-products) are harmful compounds formed when proteins or fats combine with sugars in the bloodstream through a process called glycation. This process is closely linked to various chronic diseases, including diabetes, cardiovascular diseases, and neurodegenerative disorders. Research has shown that elevated levels of AGEs contribute to inflammation, oxidative stress, and tissue damage, making them significant targets for therapeutic interventions. The study of AGE recombinant proteins has gained attention as a potential strategy to better understand their biological effects and mechanisms of action. By producing AGE-modified proteins in a controlled environment, researchers can investigate how different AGEs interact with cellular receptors and signaling pathways, ultimately influencing pathological states. Moreover, these recombinant proteins can serve as valuable tools in developing diagnostic assays and therapeutic agents aimed at mitigating the effects of AGEs in disease conditions. As the prevalence of AGE-associated diseases continues to rise, advancing our knowledge of these compounds through recombinant technology is crucial for devising effective prevention and treatment strategies. This research is pivotal not only for enhancing our understanding of AGE impact on human health but also for fostering the development of AGE-targeting drugs, thereby potentially improving patient outcomes in various age-related and metabolic diseases.
